NuVasive, Inc. (NUVA) Insider Matthew Link Sells 1,200 Shares of Stock
NuVasive, Inc. (NASDAQ:NUVA) insider Matthew Link sold 1,200 shares of NuVasive stock in a transaction on Friday, November 16th. The shares were sold at an average price of $62.01, for a total transaction of $74,412.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Matthew Link also recently made the following trade(s):
- On Monday, November 19th, Matthew Link sold 2,582 shares of NuVasive stock. The shares were sold at an average price of $62.02, for a total transaction of $160,135.64.
Shares of NASDAQ NUVA traded up $1.10 during trading on Wednesday, hitting $62.61. 52,579 shares of the company were exchanged, compared to its average volume of 803,705. The firm has a market capitalization of $3.15 billion, a P/E ratio of 32.78, a PEG ratio of 1.84 and a beta of 0.78. NuVasive, Inc. has a 1 year low of $44.62 and a 1 year high of $72.41. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.83 and a current ratio of 3.45.
Several hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio boosted its position in shares of NuVasive by 45.5% in the 2nd quarter. Strs Ohio now owns 3,200 shares of the medical device company’s stock worth $166,000 after buying an additional 1,000 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of NuVasive by 163.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,469 shares of the medical device company’s stock worth $175,000 after buying an additional 1,533 shares in the last quarter. Honkamp Krueger Financial Services Inc. purchased a new stake in shares of NuVasive in the 3rd quarter worth about $183,000. Sun Life Financial INC purchased a new stake in shares of NuVasive in the 2nd quarter worth about $201,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of NuVasive in the 3rd quarter worth about $209,000.
NUVA has been the topic of a number of analyst reports. Needham & Company LLC lowered their price objective on shares of NuVasive from $69.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, August 1st. Robert W. Baird upgraded shares of NuVasive from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $60.00 to $82.00 in a research report on Thursday, September 27th. ValuEngine upgraded shares of NuVasive from a “strong sell” rating to a “sell” rating in a research report on Monday, July 30th. Cantor Fitzgerald reiterated a “hold” rating and issued a $58.00 price objective on shares of NuVasive in a research report on Friday, October 19th. Finally, Morgan Stanley lifted their price objective on shares of NuVasive from $55.00 to $77.00 and gave the company a “hold” rating in a research report on Tuesday, September 25th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $67.47.
NuVasive Company Profile
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Article: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.